{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T20:16:46Z","timestamp":1789676206570,"version":"4.0.1"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2012,9,26]],"date-time":"2012-09-26T00:00:00Z","timestamp":1348617600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1007\/s40263-012-0004-3","type":"journal-article","created":{"date-parts":[[2012,12,17]],"date-time":"2012-12-17T20:10:27Z","timestamp":1355775027000},"page":"993-1001","source":"Crossref","is-referenced-by-count":23,"title":["Stiripentol"],"prefix":"10.1007","volume":"26","author":[{"given":"Greg L.","family":"Plosker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,9,26]]},"reference":[{"issue":"3","key":"4_CR1","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.jpeds.2010.10.035","volume":"158","author":"RP Morse","year":"2011","unstructured":"Morse RP. Dravet syndrome: inroads into understanding epileptic encephalopathies. J Pediatr. 2011;158(3):354\u20139.","journal-title":"J Pediatr"},{"issue":"Suppl. 2","key":"4_CR2","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1528-1167.2006.00688.x","volume":"47","author":"M Wolff","year":"2006","unstructured":"Wolff M, Casse-Perrot C, Dravet C. Severe myoclonic epilepsy of infants (Dravet syndrome): natural history and neuropsychological findings. Epilepsia. 2006;47(Suppl. 2):45\u20138.","journal-title":"Epilepsia"},{"issue":"Suppl. 2","key":"4_CR3","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1528-1167.2011.02999.x","volume":"52","author":"F Guzzetta","year":"2011","unstructured":"Guzzetta F. Cognitive and behavioral characteristics of children with Dravet syndrome: an overview. Epilepsia. 2011;52(Suppl. 2):35\u20138.","journal-title":"Epilepsia"},{"issue":"Suppl. 2","key":"4_CR4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1469-8749.2011.03964.x","volume":"53","author":"C Dravet","year":"2011","unstructured":"Dravet C. Dravet syndrome history. Dev Med Child Neurol. 2011;53(Suppl. 2):1\u20136.","journal-title":"Dev Med Child Neurol"},{"key":"4_CR5","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1111\/j.1528-1157.1990.tb05494.x","volume":"31","author":"DL Hurst","year":"1990","unstructured":"Hurst DL. Epidemiology of severe myoclonic epilepsy of infancy. Epilepsia. 1990;31:397\u2013400.","journal-title":"Epilepsia"},{"issue":"Suppl. 2","key":"4_CR6","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1528-1167.2011.03002.x","volume":"52","author":"M Sakauchi","year":"2011","unstructured":"Sakauchi M, Oguni H, Kato I, et al. Mortality in Dravet syndrome: search for risk factors in Japanese patients. Epilepsia. 2011;52(Suppl. 2):50\u20134.","journal-title":"Epilepsia"},{"issue":"Suppl. 2","key":"4_CR7","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1469-8749.2011.03967.x","volume":"53","author":"C Chiron","year":"2011","unstructured":"Chiron C. Current therapeutic procedures in Dravet syndrome. Dev Med Child Neurol. 2011;53(Suppl. 2):16\u20138.","journal-title":"Dev Med Child Neurol"},{"issue":"11","key":"4_CR8","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1016\/S0929-693X(02)00090-8","volume":"9","author":"TN Thanh","year":"2002","unstructured":"Thanh TN, Chiron C, Dellatolas G, et al. Long-term efficacy and tolerance of stiripentol in severe myoclonic epilepsy of infancy (Dravet\u2019s syndrome) [in French]. Arch Pediatr. 2002;9(11):1120\u20137.","journal-title":"Arch Pediatr"},{"issue":"5","key":"4_CR9","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/j.1528-1157.1998.tb01413.x","volume":"39","author":"R Guerrini","year":"1998","unstructured":"Guerrini R, Dravet C, Genton P, et al. Lamotrigine and seizure aggravation in severe myoclonic epilepsy. Epilepsia. 1998;39(5):508\u201312.","journal-title":"Epilepsia"},{"issue":"4","key":"4_CR10","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1177\/088307389701200407","volume":"12","author":"A Lortie","year":"1997","unstructured":"Lortie A, Chiron C, Dumas C, et al. Optimizing the indication of vigabatrin in children with refractory epilepsy. J Child Neurol. 1997;12(4):253\u20139.","journal-title":"J Child Neurol"},{"key":"4_CR11","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0920-1211(97)00080-6","volume":"29","author":"SJ Wallace","year":"1998","unstructured":"Wallace SJ. Myoclonus and epilepsy in childhood: a review of treatment with valproate, ethosuximide, lamotrigine and zonisamide. Epilepsy Res. 1998;29:147\u201354.","journal-title":"Epilepsy Res"},{"issue":"9242","key":"4_CR12","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(00)03157-3","volume":"356","author":"C Chiron","year":"2000","unstructured":"Chiron C, Marchand MC, Tran A, et al. Stiripentol in severe myoclonic epilepsy in infancy: a randomised placebo-controlled syndrome-dedicated trial. Lancet. 2000;356(9242):1638\u201342.","journal-title":"Lancet"},{"issue":"3","key":"4_CR13","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1212\/01.wnl.0000265222.24102.db","volume":"69","author":"P Striano","year":"2007","unstructured":"Striano P, Coppola A, Pezzella M, et al. An open-label trial of levetiracetam in severe myoclonic epilepsy of infancy. Neurology. 2007;69(3):250\u20134.","journal-title":"Neurology"},{"issue":"8","key":"4_CR14","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1053\/seiz.2000.0466","volume":"9","author":"M Nieto-Barrera","year":"2000","unstructured":"Nieto-Barrera M, Candau R, Nieto-Jimenez M, et al. Topiramate in the treatment of severe myoclonic epilepsy in infancy. Seizure. 2000;9(8):590\u20134.","journal-title":"Seizure"},{"issue":"6","key":"4_CR15","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1055\/s-2007-964867","volume":"37","author":"J Kroll-Seger","year":"2006","unstructured":"Kroll-Seger J, Portilla P, Dulac O, et al. Topiramate in the treatment of highly refractory patients with Dravet syndrome. Neuropediatrics. 2006;37(6):325\u20139.","journal-title":"Neuropediatrics"},{"issue":"10","key":"4_CR16","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.braindev.2008.03.002","volume":"30","author":"T Tanabe","year":"2008","unstructured":"Tanabe T, Awaya Y, Matsuishi T, et al. Management of and prophylaxis against status epilepticus in children with severe myoclonic epilepsy in infancy (SMEI; Dravet syndrome): a nationwide questionnaire survey in Japan. Brain Dev. 2008;30(10):629\u201335.","journal-title":"Brain Dev"},{"issue":"1","key":"4_CR17","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.nurt.2006.10.001","volume":"4","author":"Chiron C Stiripentol","year":"2007","unstructured":"Stiripentol Chiron C. Neurotherapeutics. 2007;4(1):123\u20135.","journal-title":"Neurotherapeutics"},{"key":"4_CR18","unstructured":"Diacomit\u00ae (stiripentol): EU summary of product characteristics. Gentilly: Biocodex, 2007 Jan 4."},{"issue":"2","key":"4_CR19","first-page":"199","volume":"34","author":"M Poisson","year":"1984","unstructured":"Poisson M, Huguet F, Savattier A, et al. A new type of anticonvulsant, stiripentol: pharmacological profile and neurochemical study. Arzneimittelforschung. 1984;34(2):199\u2013204.","journal-title":"Arzneimittelforschung"},{"issue":"4","key":"4_CR20","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1111\/j.1528-1167.2006.00497.x","volume":"47","author":"PP Quilichini","year":"2006","unstructured":"Quilichini PP, Chiron C, Ben-Ari Y, et al. Stiripentol, a putative antiepileptic drug, enhances the duration of opening of GABAA-receptor channels. Epilepsia. 2006;47(4):704\u201316.","journal-title":"Epilepsia"},{"issue":"2","key":"4_CR21","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ejphar.2010.12.037","volume":"654","author":"JL Fisher","year":"2011","unstructured":"Fisher JL. Interactions between modulators of the GABAA receptor: stiripentol and benzodiazepines. Eur J Pharmacol. 2011;654(2):160\u20135.","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"4_CR22","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.neuropharm.2008.06.004","volume":"56","author":"JL Fisher","year":"2009","unstructured":"Fisher JL. The anticonvulsant stiripentol acts directly on the GABAA receptor as a positive allosteric modulator. Neuropharmacology. 2009;56(1):190\u20137.","journal-title":"Neuropharmacology"},{"key":"4_CR23","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1528-1167.2011.03008.x","volume":"52","author":"JL Fisher","year":"2011","unstructured":"Fisher JL. The effects of stiripentol on GABAA receptors. Epilepsia. 2011;52:76\u20138.","journal-title":"Epilepsia"},{"key":"4_CR24","volume-title":"Stiripentol: an example of antiepileptic drug development in childhood epilepsies","author":"R Nabbout","year":"2012","unstructured":"Nabbout R, Chiron C. Stiripentol: an example of antiepileptic drug development in childhood epilepsies. Epub: Eur J Paediatr Neurol; 2012."},{"key":"4_CR25","unstructured":"Grosenbaugh DK, Mott DD. Stiripentol is active in status epilepticus model [abstract]. Eleventh Eilat Conference on New Antiepileptic Drugs. Eilat; 2012 May 6\u201310."},{"key":"4_CR26","unstructured":"Verleye M, Callizot N, Steinschneider R. Neuroprotective potential of stiripentol against oxygen and glucose deprivation or glutamate exposure in cultured rat cortical neurons [abstract]. Eleventh Eilat Conference on New Antiepileptic Drugs. Eilat; 2012 May 6\u201310."},{"issue":"7","key":"4_CR27","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1111\/j.1528-1167.2012.03497.x","volume":"53","author":"D Cao","year":"2012","unstructured":"Cao D, Ohtani H, Ogiwara I, et al. Efficacy of stiripentol in hyperthermia-induced seizures in a mouse model of Dravet syndrome. Epilepsia. 2012;53(7):1140\u20135.","journal-title":"Epilepsia"},{"issue":"6","key":"4_CR28","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/S0090-9556(25)08990-1","volume":"14","author":"TA Moreland","year":"1986","unstructured":"Moreland TA, Astoin J, Lepage F, et al. The metabolic fate of stiripentol in man. Drug Metab Dispos. 1986;14(6):654\u201362.","journal-title":"Drug Metab Dispos"},{"issue":"11\u201312","key":"4_CR29","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1002\/j.1552-4604.1983.tb01799.x","volume":"23","author":"RH Levy","year":"1983","unstructured":"Levy RH, Lin HS, Blehaut HM, et al. Pharmacokinetics of stiripentol in normal man: evidence of nonlinearity. J Clin Pharmacol. 1983;23(11\u201312):523\u201333.","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"4_CR30","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1528-1157.1984.tb03448.x","volume":"25","author":"RH Levy","year":"1984","unstructured":"Levy RH, Loiseau P, Guyot M, et al. Michaelis\u2013Menten kinetics of stiripentol in normal humans. Epilepsia. 1984;25(4):486\u201391.","journal-title":"Epilepsia"},{"issue":"5","key":"4_CR31","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/clpt.1984.237","volume":"36","author":"RH Levy","year":"1984","unstructured":"Levy RH, Loiseau P, Guyot M, et al. Stiripentol kinetics in epilepsy: nonlinearity and interactions. Clin Pharmacol Ther. 1984;36(5):661\u20139.","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"4_CR32","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/0920-1211(94)90001-9","volume":"18","author":"RH Arends","year":"1994","unstructured":"Arends RH, Zhang K, Levy RH, et al. Stereoselective pharmacokinetics of stiripentol: an explanation for the development of tolerance to anticonvulsant effect. Epilepsy Res. 1994;18(2):91\u20136.","journal-title":"Epilepsy Res"},{"issue":"1","key":"4_CR33","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0920-1211(92)90088-B","volume":"12","author":"DD Shen","year":"1992","unstructured":"Shen DD, Levy RH, Savitch JL, et al. Comparative anticonvulsant potency and pharmacokinetics of (+)-and (\u2212)-enantiomers of stiripentol. Epilepsy Res. 1992;12(1):29\u201336.","journal-title":"Epilepsy Res"},{"issue":"5","key":"4_CR34","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S0009-9236(97)90044-8","volume":"62","author":"A Tran","year":"1997","unstructured":"Tran A, Rey E, Pons G, et al. Influence of stiripentol on cytochrome P450-mediated metabolic pathways in humans: in vitro and in vivo comparison and calculation of in vivo inhibition constants. Clin Pharmacol Ther. 1997;62(5):490\u2013504.","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"4_CR35","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1046\/j.0306-5251.2003.01919.x","volume":"56","author":"N Cazali","year":"2003","unstructured":"Cazali N, Tran A, Treluyer JM, et al. Inhibitory effect of stiripentol on carbamazepine and saquinavir metabolism in human. Br J Clin Pharmacol. 2003;56(5):526\u201336.","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"4_CR36","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1528-1157.1991.tb05254.x","volume":"32","author":"BM Kerr","year":"1991","unstructured":"Kerr BM, Martinez-Lage JM, Viteri C, et al. Carbamazepine dose requirements during stiripentol therapy: influence of cytochrome P-450 inhibition by stiripentol. Epilepsia. 1991;32(2):267\u201374.","journal-title":"Epilepsia"},{"issue":"4","key":"4_CR37","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1124\/dmd.105.007237","volume":"34","author":"C Giraud","year":"2006","unstructured":"Giraud C, Treluyer J-M, Rey E, et al. In vitro and in vivo inhibitory effect of stiripentol on clobazam metabolism. Drug Metab Dispos. 2006;34(4):608\u201311.","journal-title":"Drug Metab Dispos"},{"key":"4_CR38","doi-asserted-by":"crossref","unstructured":"Farwell JR, Anderson GD, Kerr BM, et al. Stiripentol in atypical absence seizures in children: an open trial. Epilepsia. 1993 Mar\u2013Apr; 34 (2):305\u201311.","DOI":"10.1111\/j.1528-1157.1993.tb02416.x"},{"issue":"4","key":"4_CR39","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1097\/FTD.0b013e31825dc4a6","volume":"34","author":"TW May","year":"2012","unstructured":"May TW, Boor R, Mayer T, et al. Concentrations of stiripentol in children and adults with epilepsy: the influence of dose, age, and comedication. Ther Drug Monit. 2012;34(4):390\u20137.","journal-title":"Ther Drug Monit"},{"issue":"11","key":"4_CR40","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1111\/j.1528-1157.1999.tb02048.x","volume":"40","author":"J Perez","year":"1999","unstructured":"Perez J, Chiron C, Musial C, et al. Stiripentol: efficacy and tolerability in children with epilepsy. Epilepsia. 1999;40(11):1618\u201326.","journal-title":"Epilepsia"},{"issue":"2","key":"4_CR41","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/j.1528-1167.2007.01423.x","volume":"49","author":"B Kassai","year":"2008","unstructured":"Kassai B, Chiron C, Augier S, et al. Severe myoclonic epilepsy in infancy: a systematic review and a meta-analysis of individual patient data. Epilepsia. 2008;49(2):343\u20138.","journal-title":"Epilepsia"},{"issue":"11","key":"4_CR42","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1111\/j.1528-1167.2009.02179.x","volume":"50","author":"Y Inoue","year":"2009","unstructured":"Inoue Y, Ohtsuka Y, Oguni H, et al. Stiripentol open study in Japanese patients with Dravet syndrome. Epilepsia. 2009;50(11):2362\u20138.","journal-title":"Epilepsia"},{"issue":"7","key":"4_CR43","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1111\/j.1528-1167.2011.03107.x","volume":"52","author":"R Nabbout","year":"2011","unstructured":"Nabbout R, Copioli C, Chipaux M, et al. Ketogenic diet also benefits Dravet syndrome patients receiving stiripentol: a prospective pilot study. Epilepsia. 2011;52(7):e54\u20137.","journal-title":"Epilepsia"},{"issue":"Suppl 2","key":"4_CR44","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1528-1167.2011.03007.x","volume":"52","author":"C Chiron","year":"2011","unstructured":"Chiron C, Dulac O. The pharmacologic treatment of Dravet syndrome. Epilepsia. 2011;52(Suppl 2):72\u20135.","journal-title":"Epilepsia"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-012-0004-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-012-0004-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-012-0004-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T20:08:53Z","timestamp":1745438933000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-012-0004-3"}},"subtitle":["In Severe Myoclonic Epilepsy of Infancy (Dravet Syndrome)"],"short-title":[],"issued":{"date-parts":[[2012,9,26]]},"references-count":44,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["4"],"URL":"https:\/\/doi.org\/10.1007\/s40263-012-0004-3","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9,26]]}}}